Observational studyRMD open2020

Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study.

Alain Saraux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.